515 results on '"Galetta, D."'
Search Results
2. A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study
3. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
4. Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis
5. Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution
6. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
7. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study
8. LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study
9. Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey
10. P4.14C.04 Exhaled Breath Analysis for the Early Diagnosis of Malignant Pleural Mesothelioma and the Surveillance of Asbestos-Exposed At-Risk Subjects.
11. MA04.08 High Recruitment Rate and Performance of a National Lung Cancer Screening Network Implementing Web-Based Instruments
12. 1912P AI-based early prediction of radiation pneumonitis in stage III NSCLC patients
13. 1689TiP The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
14. 1283P Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
15. A survey on smoking and tobacco control perceptions from physicians and employees working in an Italian cancer center: 40P
16. 2001P Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
17. 2128P exerCise discussion with Oncologist duriNg caNcEr ConsultaTion: The CONNECT study
18. 1510TiP Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
19. Results of thoracoscopic pleural abrasion for primary spontaneous pneumothorax
20. 92P Predictors, surrogate and patient-reported outcomes in neoadjuvant immunotherapy for lung cancer: A single-center retrospective study
21. Treatment of advanced non-small cell lung cancer
22. 1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
23. EP16.03-040 Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base
24. Italian clinical research in non-small-cell lung cancer
25. Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials
26. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA–IIIB) non-small-cell lung cancer: long-term results according to downstaging
27. Extrathymic malignancies in patients with thymoma
28. Erratum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases (Scientific Reports (2015) 5 (18670) DOI: 10.1038/srep18670)
29. LBA47 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
30. Giant solitary fibrous tumor of the pleura requiring left pneumonectomy
31. Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study
32. Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program
33. 104P Fast progression in high PD-L1 NSCLC treated with pembrolizumab in first-line: A prognostic scoring system based on clinical features
34. P75.21 Impact of Diagnosis and Treatment of Concurrent Infections during Immunotherapy in Advanced Lung Cancer: A Retrospective Cohort Study
35. P78.12 A Rare Case of Dermatomyositis as Late Immune-Related Toxicity During Anti-PD1 Treatment for Advanced Lung Cancer
36. P75.14 Gender-Related Safety and Outcome in Advanced NSCLC Patients Treated with Immune Checkpoint-Inhibitors. A Real-World Experience
37. P40.01 Tobacco use in Adolescence and Associated Factors: Products, School, Family, Peers and Movies in Pandemic Period
38. FP06.04 Psychological Distress in Outpatients with Lymphoma, Lung and Breast Cancer during COVID-19 pandemic
39. 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
40. 55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study
41. 1746P - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC
42. 1588TiP - The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer
43. 1568P - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
44. 1518P - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest
45. 1489PD - Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial
46. EP1.17-19 Robotic-Assisted Thoracic Surgery for Early Stage Lung Cancer: Ten Years' Single Institution Experience
47. EP1.04-38 A Case of Lichenoid Reaction as Late and Uncommon Immune-Related Skin Toxicity During Nivolumab Treatment
48. EP1.01-81 Resection of Tumors with Carinal Involvement After Induction Therapy
49. EP1.01-56 Co-Presentation of Adenocarcinoma and Squamous Cell Lung Carcinoma Harbouring ALK Rearrangement in Different Sites
50. EP1.01-44 Early and Long-Term Results of Tracheal Sleeve Pneumonectomy for Lung Cancer After Induction Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.